Citations 1
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
Stewart, A. Keith, Trudel, Suzanne , White, Darrell , Sabry, Waleed , Belch, Andrew R. , Reiman, Tony , Roy, Jean , Shustik, Chaim, Kovacs, Michael J., Rubinger, Morel, Cantin, Guy, Song, Kevin , Tompkins, Kirsty A., Marcellus, Deb C., Lacy, Martha Q. , Sussman, Jonathan , Reece, Donna , Brundage, Michael , Harnett, Erica, Shepherd, Lois E. , Chapman, Judy-Anne W., Meyer, Ralph M., Bahlis, Nizar Jacques , Marcellus, Deborah, Chapman, Judy‐Anne W.
Blood | January 8, 2013 | Volume: 121 | Issue: 9 | Pages: 1517-1523
Key Points Thalidomide and prednisone maintenance after transplantation improves progression-free but not overall survival.